Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Theodore Randolph to Recombinant Proteins

This is a "connection" page, showing publications Theodore Randolph has written about Recombinant Proteins.

 
Connection Strength
  
 
 
4.223
  
  1. Snell JR, Kumar NSK, Suryanarayanan R, Randolph TW. Nanobubbles in Reconstituted Lyophilized Formulations: Interaction With Proteins and Mechanism of Formation. J Pharm Sci. 2020 01; 109(1):284-292.
    View in: PubMed
    Score: 0.521
  2. Xu Y, Grobelny P, Von Allmen A, Knudson K, Pikal M, Carpenter JF, Randolph TW. Protein quantity on the air-solid interface determines degradation rates of human growth hormone in lyophilized samples. J Pharm Sci. 2014 May; 103(5):1356-66.
    View in: PubMed
    Score: 0.364
  3. Hassett KJ, Cousins MC, Rabia LA, Chadwick CM, O'Hara JM, Nandi P, Brey RN, Mantis NJ, Carpenter JF, Randolph TW. Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization. Eur J Pharm Biopharm. 2013 Oct; 85(2):279-86.
    View in: PubMed
    Score: 0.341
  4. Crisman RL, Randolph TW. Refolding of proteins from inclusion bodies is favored by a diminished hydrophobic effect at elevated pressures. Biotechnol Bioeng. 2009 Feb 01; 102(2):483-92.
    View in: PubMed
    Score: 0.255
  5. Seefeldt MB, Crouch C, Kendrick B, Randolph TW. Specific volume and adiabatic compressibility measurements of native and aggregated recombinant human interleukin-1 receptor antagonist: density differences enable pressure-modulated refolding. Biotechnol Bioeng. 2007 Oct 01; 98(2):476-85.
    View in: PubMed
    Score: 0.233
  6. Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, Carpenter JF, Randolph TW. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci. 2007 Feb; 96(2):268-79.
    View in: PubMed
    Score: 0.222
  7. Chi EY, Kendrick BS, Carpenter JF, Randolph TW. Population balance modeling of aggregation kinetics of recombinant human interleukin-1 receptor antagonist. J Pharm Sci. 2005 Dec; 94(12):2735-48.
    View in: PubMed
    Score: 0.205
  8. Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci. 2005 Feb; 94(2):256-74.
    View in: PubMed
    Score: 0.194
  9. Sorret LL, DeWinter MA, Schwartz DK, Randolph TW. Protein-protein interactions controlling interfacial aggregation of rhIL-1ra are not described by simple colloid models. Protein Sci. 2018 07; 27(7):1191-1204.
    View in: PubMed
    Score: 0.120
  10. Christie M, Peritt D, Torres RM, Randolph TW, Carpenter JF. The Role of Protein Excipient in Driving Antibody Responses to Erythropoietin. J Pharm Sci. 2015 Dec; 104(12):4041-4055.
    View in: PubMed
    Score: 0.101
  11. Randolph TW, Schiltz E, Sederstrom D, Steinmann D, Mozziconacci O, Sch?neich C, Freund E, Ricci MS, Carpenter JF, Lengsfeld CS. Do not drop: mechanical shock in vials causes cavitation, protein aggregation, and particle formation. J Pharm Sci. 2015 Feb; 104(2):602-11.
    View in: PubMed
    Score: 0.095
  12. Christie M, Torres RM, Kedl RM, Randolph TW, Carpenter JF. Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration. J Pharm Sci. 2014 Jan; 103(1):128-39.
    View in: PubMed
    Score: 0.089
  13. Van Beers MM, Gilli F, Schellekens H, Randolph TW, Jiskoot W. Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. J Pharm Sci. 2012 Jan; 101(1):187-99.
    View in: PubMed
    Score: 0.077
  14. Fradkin AH, Carpenter JF, Randolph TW. Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins. J Pharm Sci. 2011 Nov; 100(11):4953-64.
    View in: PubMed
    Score: 0.075
  15. Alford JR, Fowler AC, Wuttke DS, Kerwin BA, Latypov RF, Carpenter JF, Randolph TW. Effect of benzyl alcohol on recombinant human interleukin-1 receptor antagonist structure and hydrogen-deuterium exchange. J Pharm Sci. 2011 Oct; 100(10):4215-24.
    View in: PubMed
    Score: 0.075
  16. Crisman RL, Randolph TW. Crystallization of recombinant human growth hormone at elevated pressures: pressure effects on PEG-induced volume exclusion interactions. Biotechnol Bioeng. 2010 Nov 01; 107(4):663-72.
    View in: PubMed
    Score: 0.072
  17. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci. 2010 May; 99(5):2200-8.
    View in: PubMed
    Score: 0.070
  18. Fradkin AH, Boand CS, Eisenberg SP, Rosendahl MS, Randolph TW. Recombinant murine growth hormone from E. coli inclusion bodies: expression, high-pressure solubilization and refolding, and characterization of activity and structure. Biotechnol Prog. 2010 May-Jun; 26(3):743-9.
    View in: PubMed
    Score: 0.070
  19. Fradkin AH, Carpenter JF, Randolph TW. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci. 2009 Sep; 98(9):3247-64.
    View in: PubMed
    Score: 0.066
  20. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2009 Apr; 98(4):1201-5.
    View in: PubMed
    Score: 0.065
  21. Alford JR, Kendrick BS, Carpenter JF, Randolph TW. High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics. J Pharm Sci. 2008 Aug; 97(8):3005-21.
    View in: PubMed
    Score: 0.062
  22. Alford JR, Kwok SC, Roberts JN, Wuttke DS, Kendrick BS, Carpenter JF, Randolph TW. High concentration formulations of recombinant human interleukin-1 receptor antagonist: I. Physical characterization. J Pharm Sci. 2008 Aug; 97(8):3035-50.
    View in: PubMed
    Score: 0.062
  23. Lee SH, Carpenter JF, Chang BS, Randolph TW, Kim YS. Effects of solutes on solubilization and refolding of proteins from inclusion bodies with high hydrostatic pressure. Protein Sci. 2006 Feb; 15(2):304-13.
    View in: PubMed
    Score: 0.052
  24. Seefeldt MB, Kim YS, Tolley KP, Seely J, Carpenter JF, Randolph TW. High-pressure studies of aggregation of recombinant human interleukin-1 receptor antagonist: thermodynamics, kinetics, and application to accelerated formulation studies. Protein Sci. 2005 Sep; 14(9):2258-66.
    View in: PubMed
    Score: 0.050
  25. Roy S, Jung R, Kerwin BA, Randolph TW, Carpenter JF. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. J Pharm Sci. 2005 Feb; 94(2):382-96.
    View in: PubMed
    Score: 0.048
  26. Zhang Y, Roy S, Jones LS, Krishnan S, Kerwin BA, Chang BS, Manning MC, Randolph TW, Carpenter JF. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution. J Pharm Sci. 2004 Dec; 93(12):3076-89.
    View in: PubMed
    Score: 0.048
  27. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci. 2003 May; 12(5):903-13.
    View in: PubMed
    Score: 0.043
  28. Webb SD, Cleland JL, Carpenter JF, Randolph TW. Effects of annealing lyophilized and spray-lyophilized formulations of recombinant human interferon-gamma. J Pharm Sci. 2003 Apr; 92(4):715-29.
    View in: PubMed
    Score: 0.043
  29. Webb SD, Golledge SL, Cleland JL, Carpenter JF, Randolph TW. Surface adsorption of recombinant human interferon-gamma in lyophilized and spray-lyophilized formulations. J Pharm Sci. 2002 Jun; 91(6):1474-87.
    View in: PubMed
    Score: 0.040
  30. St John RJ, Carpenter JF, Randolph TW. High pressure fosters protein refolding from aggregates at high concentrations. Proc Natl Acad Sci U S A. 1999 Nov 09; 96(23):13029-33.
    View in: PubMed
    Score: 0.034
  31. Jones LS, Cipolla D, Liu J, Shire SJ, Randolph TW. Investigation of protein-surfactant interactions by analytical ultracentrifugation and electron paramagnetic resonance: the use of recombinant human tissue factor as an example. Pharm Res. 1999 Jun; 16(6):808-12.
    View in: PubMed
    Score: 0.033
  32. Heller MC, Carpenter JF, Randolph TW. Protein formulation and lyophilization cycle design: prevention of damage due to freeze-concentration induced phase separation. Biotechnol Bioeng. 1999 Apr 20; 63(2):166-74.
    View in: PubMed
    Score: 0.032
  33. Heller MC, Carpenter JF, Randolph TW. Conformational stability of lyophilized PEGylated proteins in a phase-separating system. J Pharm Sci. 1999 Jan; 88(1):58-64.
    View in: PubMed
    Score: 0.032
  34. Kreilgaard L, Frokjaer S, Flink JM, Randolph TW, Carpenter JF. Effects of additives on the stability of recombinant human factor XIII during freeze-drying and storage in the dried solid. Arch Biochem Biophys. 1998 Dec 01; 360(1):121-34.
    View in: PubMed
    Score: 0.032
  35. Bam NB, Cleland JL, Yang J, Manning MC, Carpenter JF, Kelley RF, Randolph TW. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. J Pharm Sci. 1998 Dec; 87(12):1554-9.
    View in: PubMed
    Score: 0.032
  36. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW. A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma. Proc Natl Acad Sci U S A. 1998 Nov 24; 95(24):14142-6.
    View in: PubMed
    Score: 0.032
  37. Kerwin BA, Heller MC, Levin SH, Randolph TW. Effects of Tween 80 and sucrose on acute short-term stability and long-term storage at -20 degrees C of a recombinant hemoglobin. J Pharm Sci. 1998 Sep; 87(9):1062-8.
    View in: PubMed
    Score: 0.031
  38. Heller MC, Carpenter JF, Randolph TW. Manipulation of lyophilization-induced phase separation: implications for pharmaceutical proteins. Biotechnol Prog. 1997 Sep-Oct; 13(5):590-6.
    View in: PubMed
    Score: 0.029
  39. Heller MC, Carpenter JF, Randolph TW. Effects of phase separating systems on lyophilized hemoglobin. J Pharm Sci. 1996 Dec; 85(12):1358-62.
    View in: PubMed
    Score: 0.027
  40. Bam NB, Cleland JL, Randolph TW. Molten globule intermediate of recombinant human growth hormone: stabilization with surfactants. Biotechnol Prog. 1996 Nov-Dec; 12(6):801-9.
    View in: PubMed
    Score: 0.027
  41. Vessely C, Estey T, Randolph TW, Henderson I, Cooper J, Nayar R, Braun LJ, Carpenter JF. Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. J Pharm Sci. 2009 Sep; 98(9):2970-93.
    View in: PubMed
    Score: 0.017
  42. Roy S, Henderson I, Nayar R, Randolph TW, Carpenter JF. Effect of pH on stability of recombinant botulinum serotype A vaccine in aqueous solution and during storage of freeze-dried formulations. J Pharm Sci. 2008 Dec; 97(12):5132-46.
    View in: PubMed
    Score: 0.016
  43. Thirumangalathu R, Krishnan S, Bondarenko P, Speed-Ricci M, Randolph TW, Carpenter JF, Brems DN. Oxidation of methionine residues in recombinant human interleukin-1 receptor antagonist: implications of conformational stability on protein oxidation kinetics. Biochemistry. 2007 May 29; 46(21):6213-24.
    View in: PubMed
    Score: 0.014
  44. Thirumangalathu R, Krishnan S, Brems DN, Randolph TW, Carpenter JF. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci. 2006 Jul; 95(7):1480-97.
    View in: PubMed
    Score: 0.013
  45. Roy S, Katayama D, Dong A, Kerwin BA, Randolph TW, Carpenter JF. Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist. Biochemistry. 2006 Mar 28; 45(12):3898-911.
    View in: PubMed
    Score: 0.013
  46. Garzon-Rodriguez W, Koval RL, Chongprasert S, Krishnan S, Randolph TW, Warne NW, Carpenter JF. Optimizing storage stability of lyophilized recombinant human interleukin-11 with disaccharide/hydroxyethyl starch mixtures. J Pharm Sci. 2004 Mar; 93(3):684-96.
    View in: PubMed
    Score: 0.011
  47. Krishnan S, Chi EY, Webb JN, Chang BS, Shan D, Goldenberg M, Manning MC, Randolph TW, Carpenter JF. Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. Biochemistry. 2002 May 21; 41(20):6422-31.
    View in: PubMed
    Score: 0.010
  48. Jones LS, Randolph TW, Kohnert U, Papadimitriou A, Winter G, Hagmann ML, Manning MC, Carpenter JF. The effects of Tween 20 and sucrose on the stability of anti-L-selectin during lyophilization and reconstitution. J Pharm Sci. 2001 Oct; 90(10):1466-77.
    View in: PubMed
    Score: 0.010
  49. Kreilgaard L, Jones LS, Randolph TW, Frokjaer S, Flink JM, Manning MC, Carpenter JF. Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci. 1998 Dec; 87(12):1597-603.
    View in: PubMed
    Score: 0.008
  50. Kendrick BS, Cleland JL, Lam X, Nguyen T, Randolph TW, Manning MC, Carpenter JF. Aggregation of recombinant human interferon gamma: kinetics and structural transitions. J Pharm Sci. 1998 Sep; 87(9):1069-76.
    View in: PubMed
    Score: 0.008
  51. Kendrick BS, Chang BS, Arakawa T, Peterson B, Randolph TW, Manning MC, Carpenter JF. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: role in restricted conformational mobility and compaction of native state. Proc Natl Acad Sci U S A. 1997 Oct 28; 94(22):11917-22.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)